TRENTON, N.J. — There’s no evidence Merck & Co.’s blockbuster cholesterol drug Vytorin causes cancer, federal regulators said today. They reviewed reams of data after a patient study last year raised ...

More ripples from the storied Vytorin trial. With Congress looking into the familiar ads Merck and Schering-Plough used to pump up Vytorin sales, Advertising Age is bewailing the campaign's potential ...

Are you a print subscriber? Activate your account. By Jessica Wohl - 12 hours 44 min ago By Ad Age Staff - 16 hours 8 min ago By Anthony Crupi - 16 hours 30 min ago By Ad Age Studio 30 - 16 hours 39 ...

MUNICH, GERMANY — Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used ...

For two decades, that has been the mantra of heart doctors and their patients: Lower LDL, or "bad" cholesterol, reduces the risk of heart attack and stroke and prolongs life. But a controversial study ...

Last week Merck announced that its big Vytorin clinical trial, known as IMPROVE-IT, will continue until September, 2014. Vytorin is the combination of Merck’s statin, simvastatin (generic Zocor), with ...

After nearly two years of waiting, the results came out on Monday on the long-awaited heart drug Vytorin — and the news wasn’t good. Vytorin’s manufacturers, Merck and Schering-Plough, announced that ...

WHITEHOUSE STATION and KENILWORTH, N.J., July 23, 2004 — Merck/Schering-Plough Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved VYTORIN TM (ezetimibe/simvastatin ...

(CBS/AP) Patients with chronic kidney disease often face other problems, including heart failure and stroke. Vytorin to the rescue? The FDA says Merck's popular cholesterol drug helps reduce ...